1.Dual rheumatoid factor and anti-cyclic citrullinated peptide antibody positivity affects the manifestations of rheumatoid arthritis.
Li Huan Angela Marie CHAN ; Khai Pang LEONG ; Justina Wei Lynn TAN ; Xiao GAO ; Wei Qiang SEE ; Ee Tzun KOH
Singapore medical journal 2025;66(9):486-491
INTRODUCTION:
Rheumatoid factor (RF) and anti-cyclic citrullinated peptide antibody (ACPA) are used in the diagnosis and prognostication of rheumatoid arthritis (RA). We wanted to determine the specific contributions of RF and ACPA to the biological nature of RA and whether they act synergistically.
METHODS:
We identified 731 patients from our prospective multi-ethnic RA cohort and categorised them into four groups: ACPA-positive, RF-positive, doubly positive and doubly negative. We compared the demographics, Disease Activity Score-28, Health Assessment Questionnaire score, quality of life using Short Form 36 and the use of prednisolone and disease-modifying antirheumatic drugs (DMARDs) of these patient groups.
RESULTS:
Four hundred and ninety-one patients (67.2%) were ACPA+RF+, 54 (7.4%) were ACPA+RF-, 82 (11.2%) were ACPA-RF+ and 104 (14.2%) were ACPA-RF-. Mean disease duration before the study entry was not different in the four groups. Patients with older age of onset were less likely to be positive for RF and ACPA. Fewer ACPA+RF+ patients were in remission compared to those in the other groups ( P < 0.05). Erythrocyte sedimentation rate (ESR) was higher at study entry in the ACPA+RF+ group (40.4 mm/h vs. 30.6-30.9 mm/h, P < 0.05). Prednisolone and number of DMARDs used were higher in the ACPA+RF+ group compared to the doubly negative group. There were no differences in the functional status and quality of life.
CONCLUSIONS
RA patients who were positive for both ACPA and RF had lower remission rate, higher baseline ESR and required more corticosteroid and DMARD treatment compared to those who were singly positive or doubly negative. Being doubly positive confers a worse outcome to RA patients.
Humans
;
Arthritis, Rheumatoid/diagnosis*
;
Male
;
Female
;
Middle Aged
;
Rheumatoid Factor/blood*
;
Anti-Citrullinated Protein Antibodies/blood*
;
Adult
;
Quality of Life
;
Prospective Studies
;
Antirheumatic Agents/therapeutic use*
;
Aged
;
Peptides, Cyclic/immunology*
;
Prednisolone/therapeutic use*
;
Surveys and Questionnaires
;
Severity of Illness Index
;
Prognosis
2.The Effect of Bcl-6 Expression on the Prognosis of Newly Treated Double-Expressing Lymphoma Treated with R-CHOP Regimen.
Bing-Jie FAN ; Huan CHEN ; Chen-Xing SHANGGUAN ; Xi-Yang LIU ; Yu CHANG ; Lei ZHANG
Journal of Experimental Hematology 2021;29(6):1797-1801
OBJECTIVE:
To compare the treatment outcome and prognosis of the newly-treated myc
METHODS:
152 double-expression lymphoma patients (myc
RESULTS:
The median age of 152 DEL patients was 60.5 years old (15-87 years old). 85 patients (55.9%) were Ann Arbor stage III/IV. There was no significant difference in clinical data between the patients in the two groups. Multivariate Cox regression analysis showed that bcl-6 expression, ECOG score, and stage were the independent prognostic factors for the entire group of DEL patients. There was no statistical difference in ORR between the patients in the two groups (χ2=0.749, P=0.387). Kaplan-Meier survival analysis showed that PFS and OS of the bcl-6
CONCLUSION
bcl-6
Adolescent
;
Adult
;
Aged
;
Aged, 80 and over
;
Antineoplastic Combined Chemotherapy Protocols
;
Cyclophosphamide
;
Doxorubicin
;
Humans
;
Lymphoma, Large B-Cell, Diffuse/drug therapy*
;
Middle Aged
;
Prednisolone
;
Prognosis
;
Vincristine/therapeutic use*
;
Young Adult
3.Doxorubicin Hydrochloride Liposome-Based CHOP Regimen in the Initial Treatment of Elderly Patients with Diffuse Large B-Cell Lymphoma: A Retrospective Study.
Xiang-Dong WANG ; Bo GUO ; Bing ZHAI ; Bo YANG ; Hui FAN ; Xue-Chun LU ; Su-Xia LI ; Hong-Li ZHU
Journal of Experimental Hematology 2021;29(4):1136-1140
OBJECTIVE:
To evaluate the efficacy and safety of CHOP regimen based on doxorubicin hydrochloride liposome in the initial treatment of elderly patients with diffuse large B-cell lymphoma (DLBCL).
METHODS:
Thirty-one patients with DLBCL treated from January 1, 2012 to December 31, 2019 were analyzed retrospectively, their median age was 83 (71-95) years old, and all of them were in Ⅲ-Ⅳ stage, including 17 cases who had international prognostic index (IPI) ≥ 3. The patients were treated with R-CHOP and CHOP regimens based on doxorubicin hydrochloride liposome. The efficacy and safety were evaluated during and after treatment.
RESULTS:
A total of 219 chemotherapy cycles and 7 median cycles were performed in 31 patients. The overall response (OR) rate and complete remission (CR) rate was 80.7% (25/31) and 61.3% (19/31), respectively, as well as 2 cases (6.5%) stable, 4 cases (12.9%) progressive. The main toxicities were as follows: the incidence of grade Ⅲ -Ⅳ neutropenia was 29% (9/31); two patients (6.5%) developed degree Ⅰ-Ⅱ cardiac events, which were characterized by new degree Ⅰ atrioventricular block; there were no cardiac events requiring emergency treatment and discontinuation of chemotherapy. The 1-year, 2-year and 3-year overall survival rate was 83.9%, 77.4% and 61.3%, respectively. The 1-year, 2-year and 3-year progression-free survival rate was 77.4%, 64.5% and 61.3%, respectively.
CONCLUSION
The chemotherapy regimen based on doxorubicin hydrochloride liposome has better efficacy and higher cardiac safety for elderly patients with DLBCL.
Aged
;
Aged, 80 and over
;
Antineoplastic Combined Chemotherapy Protocols
;
Cyclophosphamide/therapeutic use*
;
Doxorubicin/therapeutic use*
;
Humans
;
Liposomes/therapeutic use*
;
Lymphoma, Large B-Cell, Diffuse/drug therapy*
;
Prednisolone
;
Prednisone/therapeutic use*
;
Retrospective Studies
;
Rituximab/therapeutic use*
;
Vincristine/therapeutic use*
4.History and Future of Treatment for Acute Stage Kawasaki Disease
Masahiro ISHII ; Takasuke EBATO ; Hirihisa KATO
Korean Circulation Journal 2020;50(2):112-119
Kawasaki disease is a form of vasculitis, mainly in small and medium arteries of unknown origin, occurring frequently in childhood. It is the leading form of childhood-onset acquired heart disease in developed countries and leads to complications of coronary artery aneurysms in approximately 25% of cases if left untreated. Although more than half a century has passed since Professor Tomisaku Kawasaki's first report in 1957, the cause is not yet clear. Currently, intravenous immunoglobulin therapy has been established as the standard treatment for Kawasaki disease. Various treatment strategies are still being studied under the slogan, “Ending powerful inflammation in the acute phase as early as possible and minimizing the incidence of coronary artery lesions,” as the goal of acute phase treatments for Kawasaki disease. Currently, in addition to immunoglobulin therapy, steroid therapy, therapy using infliximab, biological products, suppression of elastase secretion inside and outside the neutrophils, inactivated ulinastatin therapy and cyclosporine therapy, plasma exchange, etc. are performed. This chapter outlines the history and transition of the acute phase treatment for Kawasaki disease.
Aneurysm
;
Arteries
;
Biological Products
;
Coronary Vessels
;
Cyclosporine
;
Developed Countries
;
Heart Diseases
;
Immunization, Passive
;
Incidence
;
Inflammation
;
Infliximab
;
Mucocutaneous Lymph Node Syndrome
;
Neutrophils
;
Pancreatic Elastase
;
Plasma Exchange
;
Prednisolone
;
Vasculitis
5.Urrets-Zavalia Syndrome Following Trabeculectomy
Gi Seok PARK ; Yeo Kyoung WON ; Kyoung Nam KIM ; Yeon Hee LEE ; Chang sik KIM
Journal of the Korean Ophthalmological Society 2020;61(2):221-225
PURPOSE: We report a case of Urrets-Zavalia syndrome with a fixed dilated pupil after an uneventful trabeculectomy.CASE SUMMARY: Trabeculectomy was performed on a 51-year-old male who had a history of recurrent uveitis in the left eye, with uncontrolled intraocular pressure despite maximally-tolerated medial therapy. There was no unexpected event during surgery. Topical 1% atropine was used for only 2 days after surgery. In the early postoperative period, 1% prednisolone and 0.3% ofloxacin were given four times a day, then gradually reduced. One month later, only 1% prednisolone was given once a day. Intraocular pressure in his left eye was well controlled from 8–14 mmHg after surgery. One month after surgery, the pupils remained dilated. There was no reaction to topical 2% pilocarpine and no relative afferent pupillary defect or posterior synechia.CONCLUSIONS: Our case, although rare, suggests that Urrets-Zavalia syndrome should be considered in patients with well-controlled intraocular pressure after uneventful trabeculectomy.
Atropine
;
Humans
;
Intraocular Pressure
;
Male
;
Middle Aged
;
Ofloxacin
;
Pilocarpine
;
Postoperative Period
;
Prednisolone
;
Pupil
;
Pupil Disorders
;
Trabeculectomy
;
Uveitis
6.Clinical Features and Risk Factors of Systemic Lupus Erythematosus Complicated with Cytomegalovirus Infection.
Yu Ting TAN ; Xiao Chun SHI ; Xiao Qing LIU ; Xiao Feng ZENG ; Bao Tong ZHOU
Acta Academiae Medicinae Sinicae 2020;42(6):749-754
Objective To explore the clinical characteristics and risk factors of systemic lupus erythematosus(SLE)complicated with cytomegalovirus infection(CMV). Methods The medical records of patients diagnosed with SLE at discharge in the Department of Immunology at Peking Union Medical College Hospital between July 1,2017 and April 1,2019 were retrospectively reviewed,and the clinical and laboratory data related to CMV infection were analyzed. Results Of the 231 patients with SLE,115(49.8%)had CMV infection.Among them,78(67.8%)were asymptomatic CMV infection and 37(32.2%)were diagnosed with CMV disease.Univariate analysis showed the number of organs involved(
Cyclophosphamide/therapeutic use*
;
Cytomegalovirus Infections/epidemiology*
;
Humans
;
Immunosuppressive Agents/therapeutic use*
;
Lupus Erythematosus, Systemic/drug therapy*
;
Methylprednisolone/therapeutic use*
;
Prednisolone/therapeutic use*
;
Retrospective Studies
;
Risk Factors
;
Serum Albumin, Human/analysis*
7.Effect of prednisolone and adrenocorticotropic hormone in the treatment of infantile spasms: a Meta analysis.
Ke-Ren LUO ; Jun TANG ; De-Zhi MU
Chinese Journal of Contemporary Pediatrics 2019;21(7):656-662
OBJECTIVE:
To compare the effect and safety of prednisolone and adrenocorticotropic hormone (ACTH) in the treatment of infantile spasms (IS).
METHODS:
Cochrane Library, Embase, PubMed, China Biology Medicine Disc, CNKI, and Wanfang Data were searched for clinical studies on the comparison between prednisolone and ACTH in the treatment of IS. Literature screening, data extraction, and quality assessment were performed. Review Manager 5.3 was used for Meta analysis.
RESULTS:
Five clinical studies were included according to the inclusion criteria and exclusion criteria. Meta analysis showed that there was no significant difference in the spasm remission rate, spasm remission time, complicating infection rate, and irritability rate between the prednisolone and ACTH treatment groups (P>0.05), but the disappearance rate of hypsarrhythmia in the electroencephalogram was higher in the ACTH treatment group than in the prednisolone treatment group (P<0.05).
CONCLUSIONS
The available evidence shows no difference in the clinical efficacy of prednisolone versus ACTH in the treatment of IS. However, ACTH is superior to prednisolone in stabilizing EEG. The two therapies have no difference in the incidence of adverse reactions such as infection and irritability.
Adrenocorticotropic Hormone
;
Anticonvulsants
;
China
;
Humans
;
Infant
;
Prednisolone
;
Spasm
;
Spasms, Infantile
;
Treatment Outcome
8.Brachial Plexus Injury after Deep Sleep
Jung Min KWAK ; Jun Ho CHOI ; Dong Yoon PARK
Clinical Pain 2019;18(1):44-47
Lying on the side while falling asleep deeply after drinking or taking a sleeping pill can cause compressive neuropathy. We report a 70-year-old male patient of medial cord of left brachial plexus injury (BPI) after deep sleep. The mechanism of the injury might be compression and stretching of brachial plexus. The electrodiagnostic study was performed and the medial cord lesion of BPI was suggested. The ultrasonography image of compression site revealed the nerve swelling of medial cord of brachial plexus and median nerve at the mid-arm level. Pharmacologic treatment including oral prednisolone and exercise training were prescribed. On 6 months after initial visit, neurologic symptom and pain were improved but mild sequelae was remained.
Accidental Falls
;
Aged
;
Brachial Plexus
;
Deception
;
Drinking
;
Electrodiagnosis
;
Humans
;
Male
;
Median Nerve
;
Neurologic Manifestations
;
Prednisolone
;
Ultrasonography
9.Tacrolimus for ulcerative colitis in children: a multicenter survey in Japan
Tadahiro YANAGI ; Kosuke USHIJIMA ; Hidenobu KOGA ; Takeshi TOMOMASA ; Hitoshi TAJIRI ; Reiko KUNISAKI ; Takashi ISIHIGE ; Hiroyuki YAMADA ; Katsuhiro ARAI ; Atsushi YODEN ; Tomoki AOMATSU ; Satoru NAGATA ; Keiichi UCHIDA ; Yoshikazu OHTSUKA ; Toshiaki SHIMIZU
Intestinal Research 2019;17(4):476-485
BACKGROUND/AIMS: Tacrolimus is effective for refractory ulcerative colitis in adults, while data for children is sparse. We aimed to evaluate the effectiveness and safety of tacrolimus for induction and maintenance therapy in Japanese children with ulcerative colitis.METHODS: We retrospectively reviewed the multicenter survey data of 67 patients with ulcerative colitis aged < 17 years treated with tacrolimus between 2000 and 2012. Patients’ characteristics, disease activity, Pediatric Ulcerative Colitis Activity Index (PUCAI) score, initial oral tacrolimus dose, short-term (2-week) and long-term (1-year) outcomes, steroid-sparing effects, and adverse events were evaluated. Clinical remission was defined as a PUCAI score < 10; treatment response was defined as a PUCAI score reduction of ≥ 20 points compared with baseline.RESULTS: Patients included 35 boys and 32 girls (median [interquartile range] at admission: 13 [11–15] years). Thirty-nine patients were steroid-dependent and 26 were steroidrefractory; 20 had severe colitis and 43 had moderate colitis. The initial tacrolimus dose was 0.09 mg/kg/day (range, 0.05–0.12 mg/kg/day). The short-term clinical remission rate was 47.8%, and the clinical response rate was 37.3%. The mean prednisolone dose was reduced from 19.2 mg/day at tacrolimus initiation to 5.7 mg/day at week 8 (P< 0.001). The adverse event rate was 53.7%; 6 patients required discontinuation of tacrolimus therapy.CONCLUSIONS: Tacrolimus was a safe and effective second-line induction therapy for steroid-dependent and steroid-refractory ulcerative colitis in Japanese children.
Adult
;
Asian Continental Ancestry Group
;
Biological Factors
;
Child
;
Colectomy
;
Colitis
;
Colitis, Ulcerative
;
Female
;
Humans
;
Immunologic Factors
;
Japan
;
Prednisolone
;
Remission Induction
;
Retrospective Studies
;
Tacrolimus
;
Ulcer
10.Clinical Manifestations of PFAPA (Periodic Fever, Aphthous Stomatitis, Pharyngitis, and Adenitis) Syndrome from a Single Center
Minsoo SHIN ; Eun Hwa CHOI ; Mi Seon HAN
Pediatric Infection & Vaccine 2019;26(3):179-187
PURPOSE: Periodic fever, aphthous stomatitis, pharyngitis, and adenitis (PFAPA) syndrome is a leading cause of periodic fever in children. This study describes the clinical characteristics of PFAPA syndrome in patients from a single center.METHODS: Thirteen children diagnosed with PFAPA syndrome at Seoul National University Children's Hospital were included in this study. Retrospective medical chart reviews were performed.RESULTS: Among the 13 patients, 8 (61.5%) were male. The median follow-up duration was 3.3 years (range, 10 months–8.3 years). The median age of periodic fever onset was 3 years (range, 1–6 years). All patients had at least 5 episodes of periodic fever and pharyngitis, managed with oral antibiotics, before diagnosis. The median occurrence of fever was every 3.9 weeks and lasted for 4.2 days. All patients had pharyngitis and 12 (92.3%) had cervical lymphadenitis. Blood tests were performed for 12 patients, and no patients had neutropenia. Both the C-reactive protein and erythrocyte sedimentation rate were elevated at medians of 4.5 mg/dL (range, 0.4–13.2 mg/dL) and 29 mm/hr (range, 16–49 mm/hr), respectively. Throat swab cultures and rapid streptococcal antigen tests were negative. Nine (69.2%) patients received oral prednisolone at a median dose of 0.8 mg/kg, and in 6 (66.7%) patients, fever resolved within a few hours. Three (23.1%) patients received tonsillectomy and adenoidectomy.CONCLUSIONS: PFAPA syndrome should be considered when a child presents with periodic fever along with aphthous stomatitis, pharyngitis, or cervical lymphadenitis. Glucocorticoid administration is effective for fever resolution and can reduce unnecessary use of antibiotics.
Adenoidectomy
;
Anti-Bacterial Agents
;
Blood Sedimentation
;
C-Reactive Protein
;
Child
;
Diagnosis
;
Fever
;
Follow-Up Studies
;
Hematologic Tests
;
Humans
;
Lymphadenitis
;
Male
;
Neutropenia
;
Pharyngitis
;
Pharynx
;
Prednisolone
;
Retrospective Studies
;
Seoul
;
Stomatitis, Aphthous
;
Tonsillectomy
;
Yemen

Result Analysis
Print
Save
E-mail